1. Home
  2. Directory
  3. Texas
  4. Houston
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1215580378

CHASITY LYNNE YAJIMA FNP-C
Prescription History 1215580378
Nurse Practitioner - Family in Houston, TX


Quality Rating: 81.38 out of 100 score

NPI Status: Active since July 18, 2019

Contact Information

1515 HOLCOMBE BLVD
HOUSTON, TX
ZIP 77030
Phone: (713) 792-6161

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CHASITY LYNNE YAJIMA FNP-C, an active Family specialist practicing in Houston, TX. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 75 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 35 claims alone.

Medication Index

A
O
T
Z
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 35
30-Day Fills 94.0
Days Supply 2,820
TX State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills155.7
Peer Average Days Supply4,650
Conservative Utilization

This provider writes prescriptions for this formulation 46.2% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $915.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.16

State Avg Cost Per Claim

$24.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 151
TX State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.1
Peer Average Days Supply247
Conservative Utilization

This provider writes prescriptions for this formulation 38.9% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $67.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.12

State Avg Cost Per Claim

$7.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 14
30-Day Fills 42.0
Days Supply 1,260
TX State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills88.8
Peer Average Days Supply2,658
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.2% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $465.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.25

State Avg Cost Per Claim

$34.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Zarxio

Generic Formulation: Filgrastim-SndzSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 298
TX State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.6
Peer Average Days Supply368
Conservative Utilization

This provider writes prescriptions for this formulation 31.8% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $28,203.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,880.26

State Avg Cost Per Claim

$1,706.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant granulocyte colony-stimulating factor (G-CSF) that is used in the treatment and prevention of NEUTROPENIA, preparation and collection of blood progenitor cells, and for use in PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.

Therapeutic Applications

Filgrastim is a man-made version of a certain natural substance made by your body. It is used to help your body make more white blood cells. White blood cells are important to help you fight off infections. Filgrastim is given to people whose ability to make white blood cells is reduced (for instance, due to chemotherapy, chronic neutropenia, or exposure to large amounts of radiation). It is also used in certain treatment procedures (such as bone marrow/stem cell transplant). This monograph is about the following filgrastim products: filgrastim, tbo-filgrastim, filgrastim-sndz, filgrastim-aafi, and filgrastim-ayow.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CHASITY LYNNE YAJIMA FNP-C provides transparency into local medical care patterns within Houston, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.